Isoniazid-rifampicin induced lipid changes in rats

Clinica Chimica Acta

Volumn 389, Issue 1-2, 2008, Pages 55-60

  Pal, R ^a   Rana, S V ^a   Vaiphei, K ^a   Singh, K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Isoniazid; Lipids; Rats; Rifampicin

Indexed keywords

CHOLESTEROL; ISONIAZID PLUS RIFAMPICIN; LIPID; LIVER ENZYME; PHOSPHOLIPID DERIVATIVE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; LIVER TOXICITY; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; ANTITUBERCULAR AGENTS; FEMALE; ISONIAZID; LIPIDS; LIVER; MALE; RATS; RATS, WISTAR; RIFAMPIN;

RATTUS;

EID: 38649100629     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.11.028     Document Type: Article

References (38)

1. Yossepowitch O., and Dan M. Tuberculosis in the 21st century. Harefuah 146 (2007) 206-211
2. Fernandez V.A., Sopena B., Fernandez V.J., et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 8 (2004) 1499-1505
3. Agal S., Baijal R., Pramanik S., et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 20 (2005) 1745-1752
4. Yew W.W., and Leung C.C. Antituberculosis drugs and hepatotoxicity. Respirology 11 (2006) 699-707
5. Tahagolu K., Atae G., Sevim T., et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 5 (2001) 65-69
6. Jiang J.T., Xu N., Zhang X.Y., and Wu C.P. Lipids changes in liver cancer. J Zhejiang Univ Sci B 8 (2007) 398-409
7. Andre P., Perlemuter G., Budkowska A., Brechot C., and Lotteau V. Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis 25 (2005) 93-104
8. Bradbury M.W. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol 290 (2006) G194-G198
9. Ginsberg H.N. Is the slippery slope from steatosis to steatohepatitis paved with triglyceride or cholesterol. Cell Metab 4 (2006) 179-181
10. Rana S.V., Pal R., Vaiphie K., and Singh K. Effect of different oral doses of isoniazid-rifampicin in rats. Mol Cell Biochem 289 (2006) 39-47
11. Reitman S., and Frankel S.A. Colorimetric method for the determination of serum glutamic oxaloacetic acid and serum glutamic pyruic transaminase. Am J Clin Pathol 28 (1957) 56-63
12. Powell W.N. Serum bilirubin estimation. Am J Clin Pathol 14 (1994) 55
13. Bergmeyer M.V.C. Method of enzymatic analysis vol. 40 (1963), Academic Press, New York 783-785
14. Lowry O.H., Rosenbrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265-275
15. Folch J., Less M., and Sloane G.T. A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem 226 (1959) 497-509
16. Wybenger D.R., Pileggim B.J., Dirstina T.H., and Di Cugio J. Direct manual determination of serum total cholesterol with a single stable reagent. Clin Chem 16 (1970) 980-984
17. Stein E.A., and Myers G.L. Lipids, lipoproteins and apolipoproteins. In: Burtis C.A., and Ashwood E.R. (Eds). Tietz Textbook of clinical chemistry. Second Ed. vol. 23 (1994), WB Saunders Company 1002-1093
18. Frings C.S., Fendley T.W., Dunn R.T., and Queen C.A. Improved determination of total serum by the sulfophosphovanillin reaction. Clin Chem 18 (1972) 673-674
19. Zilversmit D.B., and Davis A.K. Microdetermination of plasma phospholipids by trichloroacetic acid precipitation. J Lab Clin Med 35 (1950) 155-160
20. Santosh S., Sini T.K., Anandan R., and Mathew P.T. Effect of chitosan supplementation on antitubercular drugs-induced hepatotoxicity in rats. Toxicol 219 (2006) 53-59
21. Sodhi C.P., Rana S.V., Mehta S.K., Vaiphei K., Attari S., and Mehta S. Study of oxidative stress in isoniazid-rifampicin induced hepatic injury in young rats. Drug Chem Toxicol 20 (1997) 255-269
22. Lee A.K., Kim E.J., and Lee M.G. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. Res Commun Mol Pathol Pharmacol 113 (2003) 193-200
23. Tredger J.M., Smith H.M., Powell-Jackson P.R., Davis M., and Williams R. Effect of rifampicin on the mouse hepatic mixed function oxidase system. Biochem Pharmacol 30 (1981) 1043-1051
24. Perry T.L., Kish S.T., Hansen S., et al. Elevation of brain GABA content by chronic low dosage administration of hydrazine, a metabolite of isoniazid. J Neurochem 37 (1981) 32-39
25. Rana S.V., Attri S., Vaiphei K., Pal R., Attri A., and Singh K. Role of N-acetylcysteine in rifampicin-induced hepatic injury of young rats. World J Gastroenterol 12 (2006) 287-291
26. Richards V.E., Chau B., White M.R., and Mc-Queen C.A. Hepatic gene expression and lipid homeostasis in C57 BL/6 mice exposed to hydrazine or acetylhydrazine. Toxicol Sci 82 (2004) 318-332
27. Sarich T.C., Adams S.P., Zhou T., and Wright J.M. Isoniazid-induced hepatic necrosis and steatosis in rabbits: absence of effect of gender. Can J Physiol Pharmacol 75 (1997) 1108-1111
28. Attri S., Rana S.V., Vaiphei K., et al. Isoniazid and rifampicin induced oxidative hepatic injury protection by n-acetylcysteine. Hum Exp Toxicol 19 (2006) 517-522
29. Lauterburg B.H., Todd E.L., Smith C.V., and Mitchell J.R. Cinetidine inhibits the formation of the reactive, toxic metabolite of isoniazid in rats but not in man. Hepatology 5 (1985) 607-609
30. Karthikeyan S. Isoniazid and rifampicin treatment in phospholipids and their subfractions in liver tissue of rabbits. Drug Chem Toxicol 28 (2005) 273-280
31. Shakun N.P., and Tabachuk O.E. The comparative action of isoniazid, rifampicin and ethambutol on liver function. Eksp Klin Farmakol 55 (1992) 45-47
32. Pari L., and Uma A. Protective effect of sesbania grandiflora against erythromycin estolate induced hepatotoxicity. Therapie 58 (2003) 439-443
33. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of non alcoholic steatohepatitis from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 (2002) 134-140
34. Khogali A.M., Chazan B.I., Metcalf V.J., and Ramsey J.H. Hyperlipidaemia as a complication of rifampicin treatment. Tubercle 55 (1974) 231-233
35. Saratikov A.S., Chuchalin V.S., Rat'kin A.V., Rat'Kin E.V., Fedoreev S.A., and Bulgakov V.P. Hepatoprotective properties of polyphenolic complexes from wood and cell culture of Maackia amurensis. Eksp Klin Farmakol 68 (2005) 51-54
36. Karthikeyan S. Isoniazid and rifampicin treatment in phospholipids and their subfractions in liver tissue of rabbits. Drug Chem Toxicol 28 (2005) 273-280
37. Piriou A., Warnet J.M., Jacqueson A., Claude J.R., and Jruhaut R. Fatty liver induced by high doss of rifampicin in the rat: possible relation with an inhibition of RNA polymerase in euleariotic cells. Arch Toxicol (suppl) 2 (1979) 333-337
38. In: Farombi E.O., Akinloy O., Akhinmoladun C.O., and Emerole G.O. (Eds). Hepatic drug metbolizing enzyme induction and serum triacylglycerol elevation in rats treated with chlordozepoxide, griseofulesin, rifampicin and phienytoin. Clin Chim Acta 289 (1999) 1-10